ReviewJournal of feline medicine and surgery2005
Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolate.
Review in Journal of feline medicine and surgery, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Dual-subtype feline immunodeficiency virus vaccine provides 12 months of protective immunity against heterologous challenge.Journal of feline medicine and surgery · 2010Trial
- Feline immunodeficiency virus: current insights into pathogenesis, clinical impact, and advances in treatment and vaccine development.Frontiers in veterinary science · 2025Review
- Feline immunodeficiency virus (FIV) infection in domestic pet cats in Australia and New Zealand: Guidelines for diagnosis, prevention and management.Australian veterinary journal · 2022Article
- Applications of the FIV Model to Study HIV Pathogenesis.Viruses · 2018Review
- FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge.NPJ vaccines · 2018Article
- First Molecular Characterization of Feline Immunodeficiency Virus in Domestic Cats from Mainland China.PloS one · 2017Article
- An investigation of the breadth of neutralizing antibody response in cats naturally infected with feline immunodeficiency virus.The Journal of general virology · 2015Article
- Article
- A door-to-door prevalence study of feline immunodeficiency virus in an Australian suburb.Journal of feline medicine and surgery · 2013Article
- Article
- Feline leukemia and feline immunodeficiency virus in Canada - A comment.The Canadian veterinary journal = La revue veterinaire canadienne · 2012Article
- Review
- Feline leukemia virus and feline immunodeficiency virus in Canada: recommendations for testing and management.The Canadian veterinary journal = La revue veterinaire canadienne · 2011Review
- Phylogenetic characterisation of naturally occurring feline immunodeficiency virus in the United Kingdom.Veterinary microbiology · 2011Article
- Current progress in the development of a prophylactic vaccine for HIV-1.Drug design, development and therapy · 2010Review
- Feline immunodeficiency virus model for designing HIV/AIDS vaccines.Current HIV research · 2010Review
- A single site for N-linked glycosylation in the envelope glycoprotein of feline immunodeficiency virus modulates the virus-receptor interaction.Retrovirology · 2008Article
- 2008 American Association of Feline Practitioners' feline retrovirus management guidelines.Journal of feline medicine and surgery · 2008Article
- Advances in FIV vaccine technology.Veterinary immunology and immunopathology · 2008Review
- Evaluation of feline monocyte-derived dendritic cells loaded with internally inactivated virus as a vaccine against feline immunodeficiency virus.Clinical and vaccine immunology : CVI · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Vaccine trials were undertaken to determine whether the Fel-O-Vax FIV, a commercial dual-subtype (subtypes A and D) feline immunodeficiency virus (FIV) vaccine, is effective against a subtype B FIV isolate. Current results demonstrate the Fel-O-Vax FIV to be effective against a subtype B virus, a subtype reported to be the most common in the USA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.